Drug intelligence / Profile preview

STC2000

Development stage: Unknown
Lead developer: Staidson Biopharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

STC2000 is an orally bioavailable small molecule therapeutic being developed by Staidson Biopharmaceutical for the treatment of gout and hyperuricemia. It functions as a urate transporter 1 (URAT1) inhibitor, a mechanism designed to lower serum uric acid levels by blocking the reabsorption of urate in the renal tubules and promoting its excretion. The drug is currently in Phase 1 clinical development, with studies evaluating its safety, tolerability, and pharmacokinetics in both healthy volunteers and patients with elevated uric acid levels.

Targets

URAT1 (Uric Acid Transporter 1)SLC22A8 (Organic anion transporter 3)OAT1 (Organic anion transporter 1)

Beyond the preview

Go deeper on STC2000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STC2000.

Explore the full profile